(BMY) Bristol-Myers Squibb Company BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BMY) Bristol-Myers Squibb Company Bundle
See the Bigger Picture
This Bristol-Myers Squibb Company BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual format and content before purchase. Buy the full version to get the complete ready-to-use report.
Stars
Eliquis, No. 1 revenue brand
Eliquis remains Bristol-Myers Squibb Company’s No. 1 revenue brand and a global DOAC leader. It delivered $13.3 billion in 2024 sales and kept broad share in atrial fibrillation and VTE prevention, with demand still rising across major markets in 2025. That scale makes it a clear Star: high growth, high share.
Opdivo, PD-1 oncology leader
Opdivo is Bristol-Myers Squibb Company’s core PD-1 asset and a clear Star in the BCG Matrix, with broad use across more than 10 cancer types and 50-plus line-extensions and combo settings. It still anchors the immuno-oncology franchise, with 2024 net sales of about $9.0 billion and steady demand in lung, renal, and melanoma care. New regimens with Yervoy and chemo keep it in growth mode, not maturity.
Reblozyl, anemia growth brand
Reblozyl is a Stars in Bristol-Myers Squibb Company’s BCG matrix: it is approved for anemia in MDS and beta thalassemia, and 2025 sales have kept climbing, with 2024 revenue above $1.2 billion. Demand is rising as hematology use broadens, and the drug’s niche leadership supports strong pricing and volume growth. That mix of label breadth and fast uptake makes it a clear growth engine for Bristol-Myers Squibb Company.
Breyanzi, CAR-T scale-up
Breyanzi is BMS’s CAR-T growth star for large B-cell lymphoma and other B-cell cancers. U.S. use widened after its 2024 second-line LBCL approval, and BMS said 2025 demand is rising as more centers adopt CAR-T and referral delays ease. The CAR-T field still has only a few approved rivals, so scale-up can keep driving sales.
- Broader label, bigger patient pool
- Physician uptake is still rising
- CAR-T remains a fast-growth niche
That makes Breyanzi a clear Star in BMS’s BCG mix: high market growth and strong share gain.
Camzyos, first-in-class HCM
Camzyos, launched in 2022 for obstructive hypertrophic cardiomyopathy (oHCM), has become one of Bristol-Myers Squibb Company’s fastest-growing newer brands, with 2024 sales at about $1.0 billion. The addressable market is still widening as diagnosis and treatment rates rise, which supports Star status in the BCG matrix.
That growth is tied to a large untreated pool: oHCM affects about 1 in 500 people, and BMS says Camzyos remains early in its launch curve.
- 2022 launch in oHCM
- ~$1.0B 2024 sales
- Fast-growing BMS brand
- Market still expanding
Bristol-Myers’ Star Brands Keep Growing: Eliquis, Opdivo, and Beyond
Bristol-Myers Squibb Company’s Stars are Eliquis, Opdivo, Reblozyl, Breyanzi, and Camzyos. They combine strong share with still-growing demand, led by Eliquis at $13.3B and Opdivo at about $9.0B in 2024, while Reblozyl, Breyanzi, and Camzyos kept scaling in 2025.
| Brand | Star signal |
|---|---|
| Eliquis | Top DOAC |
| Opdivo | IO scale |
| Camzyos | Fast launch |
What is included in the product
Detailed Word Document
Bristol-Myers Squibb’s BCG Matrix maps its drugs by growth and share to spot Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
Bristol-Myers Squibb BCG Matrix: one-page quadrant view to spot wins, cuts, and cash cows fast
Reference Sources
Provides a clean source trail for Bristol-Myers Squibb, making claims easier to verify and decisions easier to defend.
Cash Cows
Revlimid, legacy myeloma cash
Revlimid was still a cash generator for Bristol-Myers Squibb Company, with 2024 net sales of about $4.4 billion even as generic erosion deepened. The drug’s long-running multiple myeloma demand keeps it relevant, but growth is now limited and the profile is clearly mature. In BCG terms, it fits a Cash Cow: low growth, steady cash, shrinking but still meaningful contribution.
Orencia, mature RA biologic
Orencia remains a mature BMS immunology cash cow, with 2025 sales of about $2.8 billion across rheumatoid and psoriatic arthritis. The brand keeps a loyal prescriber base and still delivers useful margin, even as growth stays low. Its long market history and steady refill demand help offset slow volume pressure.
Pomalyst/Imnovid, established myeloma franchise
Pomalyst/Imnovid is a mature oral myeloma therapy with a clear clinical role in relapsed and refractory disease, so it still brings steady cash flow for Bristol Myers Squibb Company. The brand is long established and has outlasted many newer oncology launches. Growth is limited because the market is crowded and newer combo regimens are taking share.
Yervoy, stable IO combo brand
Yervoy is a mature CTLA-4 checkpoint inhibitor and still a core cash cow for Bristol-Myers Squibb Company because it is used mainly in combination regimens, not as a growth driver. In recent company reporting, Yervoy generated about $2.3 billion in annual sales, showing durable demand in melanoma and other tumors even as the brand is past peak growth.
- Used mainly in combo regimens
- Durable melanoma role
- About $2.3B annual sales
- Mature, cash-generative brand
Its value in the BCG Matrix comes from steady cash flow, strong clinical positioning, and limited need for heavy new launch spending.
Sprycel, residual CML cash
Sprycel is Bristol-Myers Squibb Company’s legacy CML cash cow: a long-running branded leukemia drug that still throws off cash, but growth has faded under patent expiry and generic pressure. Its sales are now more about harvesting residual demand than expanding share.
In the BCG view, Sprycel fits a mature, low-growth, high-cash role, with the remaining revenue stream tied to the brand’s installed base and late-stage line use.
- Legacy CML brand
- Weak growth, heavy generic pressure
- Residual sales support cash flow
Bristol-Myers’ Cash Cows Keep the Profits Flowing
Bristol-Myers Squibb Company’s Cash Cows are mature brands that still throw off strong cash despite low growth. Revlimid, Orencia, Pomalyst/Imnovid, Yervoy, and Sprycel all fit this role, with Orencia at about $2.8 billion in 2025 sales and Yervoy at about $2.3 billion annual sales.
| Brand | 2025 Sales | BCG Role |
|---|---|---|
| Orencia | $2.8B | Cash Cow |
| Yervoy | $2.3B | Cash Cow |
Get Your Copy
Bristol-Myers Squibb Company Reference Sources
The Bristol-Myers Squibb Company BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the full, professionally formatted report ready for immediate use. Once purchased, your file is instantly available for download, editing, or presentation. What you preview is what you get.
Dogs
Abraxane, genericized chemo
Abraxane, a protein-bound paclitaxel launched in 2005, is now a mature legacy oncology product for Bristol-Myers Squibb Company. Generic versions have driven sharp price and volume erosion, so growth is weak and the asset is in decline rather than expansion. In a BCG Matrix, it fits Dogs: low growth, heavy competitive pressure, and limited cash-generation upside.
Empliciti, limited-share myeloma
Empliciti stays a narrow-share myeloma antibody, with 2025 sales still under $200 million and far below Bristol-Myers Squibb Company’s top brands. In a crowded market led by larger regimens, it has not built a major franchise, so growth stays weak. That makes it a clear BCG Dog: subscale, low momentum, and limited strategic weight.
Inrebic, niche myelofibrosis
Inrebic is Bristol-Myers Squibb Company's oral JAK2 inhibitor for adult myelofibrosis, but the market is small and crowded. Myelofibrosis affects only about 1.5 people per 100,000 each year, so commercial scale stays limited. That fits a Dogs label in the BCG Matrix: low growth, narrow reach, and tough competition from better-known JAK inhibitors.
Onureg, small AML uptake
Onureg, the oral azacitidine used for AML maintenance, stayed a small BMS brand in FY2025, with sales still well below the company’s top oncology assets. Its uptake remained modest, so the product has limited growth and limited scale in the BCG matrix.
- AML maintenance use is niche.
- FY2025 sales stayed modest.
- Scale lags key oncology brands.
Zeposia, subscale immunology asset
Zeposia is used in relapsing forms of multiple sclerosis and ulcerative colitis, but it stays a subscale asset in Bristol Myers Squibb Company’s immunology set. The addressable market is large, yet Zeposia still contributes only a small slice of Bristol Myers Squibb Company’s revenue, so it is not a core growth engine. In BCG terms, it fits more like a "question mark" than a "star".
- Large market, small Bristol Myers Squibb Company share
- Used in MS and GI disease
- Growth still below top-tier assets
Bristol-Myers’ Dogs: Small, Shrinking, and Under Pressure
Abraxane, Empliciti, Inrebic, and Onureg sit in Bristol-Myers Squibb Company’s Dogs: FY2025 sales were small or declining, with weak growth, niche demand, and heavy competition. Zeposia is still subscale, so it is not a core BCG star.
| Asset | FY2025 sales | BCG |
|---|---|---|
| Abraxane | Declining | Dog |
| Empliciti | <$200M | Dog |
| Inrebic | Small | Dog |
Question Marks
Sotyktu, psoriasis launch
Sotyktu was approved in 2022 for moderate-to-severe plaque psoriasis, a market with millions of patients worldwide and about 2% to 3% global prevalence. Bristol-Myers Squibb Company is starting from a low base, so the brand needs fast share gains to move from Question Mark to Star. In BCG terms, that means rapid uptake, strong persistence, and clear differentiation versus entrenched dermatology brands.
Cobenfy, schizophrenia launch
Cobenfy, launched in 2024 for schizophrenia, is still an early bet for Bristol-Myers Squibb Company in a large CNS space. Schizophrenia affects about 24 million people worldwide, but Cobenfy still needs to win share against entrenched antipsychotics, so its 2025 uptake is still uncertain. That makes it a classic question mark with high upside and high execution risk.
Opdualag, melanoma combo launch
Opdualag, Bristol-Myers Squibb Company’s fixed-dose nivolumab and relatlimab combo for advanced melanoma, fits the Question Mark bucket: the market is growing, but share is still being built. In RELATIVITY-047, median progression-free survival was 10.1 months versus 4.6 months for nivolumab alone, supporting adoption. Upside stays tied to faster uptake and broader use in first-line advanced melanoma.
Abecma, BCMA CAR-T
Abecma is Bristol-Myers Squibb Company’s BCMA CAR-T for relapsed or refractory multiple myeloma, a fast-growing cell-therapy niche. The category is expanding, but Abecma is still battling for share against Carvykti, so it fits BCG’s question mark: high growth, weak relative position.
- BCMA CAR-T targets multiple myeloma
- High-growth cell-therapy market
- Share battle keeps it a question mark
Camzyos expansion, broader cardiology use
Camzyos is still a Question Mark in Bristol Myers Squibb Company’s BCG mix: the HCM market is growing, but it is not fully penetrated yet. The company is pushing diagnosis expansion and doctor education, so volume can still scale fast.
Market potential is high, but share is still being won case by case. That keeps Camzyos attractive, but it also means Bristol Myers Squibb Company must keep spending on awareness and echo-based diagnosis.
- Underdiagnosed HCM still limits uptake
- Education drives new patient starts
- Share growth remains the key test
5 BMS question marks with big markets but still weak share
Sotyktu, Cobenfy, Opdualag, Abecma, and Camzyos are Bristol-Myers Squibb Company question marks because they sit in large or growing markets but still need stronger share. Cobenfy targets schizophrenia, a market of about 24 million people worldwide, while Opdualag showed 10.1-month median PFS in RELATIVITY-047 versus 4.6 months for nivolumab alone. Camzyos and Abecma still depend on faster uptake and broader use.
| Brand | Signal | Key number |
|---|---|---|
| Cobenfy | Early share build | 24M schizophrenia cases |
| Opdualag | Clinical edge | 10.1 vs 4.6 months PFS |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.